Why the study?
The comparative association of apixaban versus warfarin for the treatment of venous thromboembolism in patients receiving maintenance dialysis was not well studied.
Does apixaban reduce recurrent venous thromboembolism, major bleeding, and death compared to warfarin in patients receiving maintenance dialysis with a recent venous thromboembolism?
Population
12,206 Medicare beneficiaries on dialysis following a venous thromboembolism diagnosis
Comparison
Apixaban vs warfarin
Design
Retrospective cohort study
Follow-up
6 months
Key result
Apixaban was associated with a lower risk of recurrent venous thromboembolism than warfarin in dialysis patients (HR 0.58; 95% CI 0.43 to 0.77), with no difference in mortality.
Loading...
Apixaban was associated with lower recurrent VTE and bleeding risks versus warfarin in dialysis VTE; hypothesis-generating and requires randomized confirmation.
Cohort (n=12,206)
Yes
Does apixaban reduce recurrent venous thromboembolism, major bleeding, and death compared to warfarin in patients receiving maintenance dialysis with a recent venous thromboembolism?
Hazard Ratio: 0.58 (95% CI 0.43–0.77)
In patients on maintenance dialysis with recent venous thromboembolism, apixaban is associated with lower risks of recurrent VTE and major bleeding compared to warfarin, with no difference in mortality.
A 2022 study conducted a cohort in Venous thromboembolism in patients receiving long-term dialysis (n=12,206). Apixaban vs. Warfarin was evaluated on Recurrent venous thromboembolism (HR 0.58, 95% CI 0.43 to 0.77). Apixaban was associated with a lower risk of recurrent venous thromboembolism than warfarin in dialysis patients (HR 0.58; 95% CI 0.43 to 0.77), with no difference in mortality.